In 15 closed in-house searches in Santa Clara over 36 months, Sartori's mandate telemetry records that 7 targeted biotech or diagnostics IP seats: 3 licensed-asset assistant-general-counsel chairs, 2 diagnostics patent-attorney chairs, and 2 corporate-development IP counsel chairs. Across 250 structured interviews with Santa Clara in-house counsel over 24 months, 41% said a USPTO prosecution CV without licensed-asset diligence was the last lookalike they screened out. Among 47 biotech IP respondents inside Sartori's Santa Clara interview cohort, over 24 months, 31 sat on diagnostics or biopharma IP desks rather than on tech-campus patent chairs. A six-year firm prosecutor without a diligence log is not this seat.
Day to day the licensed-asset chair owns patent strategy for products and newly acquired or licensed assets plus diligence and integration — the diet of Jazz's Executive Director, Assistant General Counsel, Intellectual Property seat at 12+ years. The Senior Director, Corporate Counsel, IP seat allows a U.S. Patent Attorney or Agent at 10+ years with in-house corporate-development diligence. Roche's 3 September 2026 Patent Attorney posting, for Pleasanton or Santa Clara, asks seven-plus years, USPTO registration, and nucleic-acid, NGS and protein-engineering work with FTO, MTAs, licensing and acquisitions.
A chief legal officer at a South Bay biopharma platform said the chair needed someone who had already lived through a portfolio integration after an acquisition. Sartori misjudges that wall on first pass: 3 of the 7 biotech IP closed files needed a rewritten shortlist after week four because the first names still sat on firm-side prosecution paper.